Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis


TÜRKOĞLU R., Baliç N., Kızılay T., Erol R., Akbayır E., YILMAZ V., ...Daha Fazla

Multiple Sclerosis and Related Disorders, cilt.58, 2022 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Kısa Makale
  • Cilt numarası: 58
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.msard.2022.103524
  • Dergi Adı: Multiple Sclerosis and Related Disorders
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Anahtar Kelimeler: COVID-19, SARS-COV-2, Vaccination, CoronaVac, Multiple sclerosis, Fingolimod
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background:: The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied. Methods:: We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individuals. Anti-SARS-CoV-2 spike IgG indices were measured by ELISA in sera of participants after CoronaVac vaccinations. Results:: Persons with MS displayed significantly lower antibody levels and seropositivity prevalence. Persons with MS with longer fingolimod treatment durations displayed lower anti-SARS-CoV-2 indices. Conclusion:: Our results support previous findings regarding humoral response impairing effect of fingolimod after vaccinations. Patients under fingolimod treatment may require closer monitoring for COVID-19.